As a trusted leader in the immunotherapy field, the Society for Immunotherapy of Cancer (SITC) collaborates with other groups to contribute toward high-quality educational programming on tumor immunology and cancer immunotherapy.
Through these educational partnerships, SITC is able to bring high quality, timely cancer immunotherapy information to learners around the world from a variety of backgrounds including scientists, academicians, researchers, clinicians, government representatives and industry leaders.
SITC offers various levels of support for the programs below, such as sharing information about unique programs, providing expert speakers to enhance programming and organizing immunotherapy sessions at relevant association meetings.
If you'd like to get in touch with the society to discuss Collaborative Education Programs, please email the SITC Live Education Department at Education@sitcancer.org.
Therapy-related myeloid neoplasms (WHO classification) with mutated TP53 or complex chromosome aberrations are not likely to be cured with targeted agents. These neoplasms comprise a group of clonal hematopoietic stem cell disorders related to prior ...
The Department of Immunology, Genetics and Pathology (IGP) at Uppsala University in Sweden is involved in an ongoing effort to collect cancer patient data in an initiative entitled U-CAN. By June of this year, the biobank has grown to approximately ...
It is the recent modest single agent activity of programmed death-ligand 1 and programmed death receptor-1 antibodies for those with breast cancer that is generating hope for use of immunotherapy in breast cancer. To ponder in the meantime, in preparation ...
FYI for those in the Tampa, FL area. Emerging Opportunities--Enhancing Awareness of Clinical Trials The 2017 Breast Immune-Oncology Conference is being held Sat., Oct. 7th at Moffitt Cancer Center. There will be a free companion Patient Advocacy Program ...
DC immunotherapy makes use of the patient's own DCs to activate cancer cell elimination.There is an inherent danger, for example, that the effect of CTLA 4 blockade is not restricted to tumor-specific T cells. resulting in immune-related toxicities that ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org